Aroda VR, Faurby M, Lophaven S, et al. - This retrospective, observational cohort study was carried out to assess the first patterns of routine clinical use of oral semaglutide, as well as to evaluate patients’ clinical characteristics and glycaemic control. Early data were presented on the use of oral semaglutide in clinical practice, from the US IBM Explorys electronic health record database. Data reported that 54.5% of the 782 patients who were prescribed oral semaglutide were women, with a mean age (SD) of 57.8 years (11.3); 66.0% of patients received their prescription from a primary care practitioner. Despite the fact that the prescribing instructions recommend raising the dose to 7 mg after 30 days, 37.3% of patients were only given a prescription for the 3 mg dose. The mean HbA1c change from baseline to about 6 months after starting oral semaglutide was -0.9%, with greater reductions in patients with higher baseline HbA1c. Such findings show that oral semaglutide is widely used in primary care, that it improves glycemic control in the real world, and that there are potential treatment gaps.